Combined therapy with low-dose omalizumab and intravenous immunoglobulin for severe atopic dermatitis. Report of four cases

Journal of the European Academy of Dermatology and Venereology

Volumn 26, Issue 10, 2012, Pages 1325-1327

  Toledo, F ^a   Silvestre, J F ^a   Munoz C ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; EFALIZUMAB; EMOLLIENT AGENT; FLEMOGAMMA; IMMUNOGLOBULIN; IMMUNOGLOBULIN E; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OMALIZUMAB; UNCLASSIFIED DRUG;

ATOPIC DERMATITIS; CLINICAL ASSESSMENT; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; HYPOTENSION; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; INJECTION SITE IRRITATION; KAPOSI VARICELLIFORM ERUPTION; LETTER; LOW DRUG DOSE; MITE; POLLEN; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; DERMATITIS, ATOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84866258544     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04326.x     Document Type: Letter

References (10)

1. Lane JE, Cheyney JM, Lane TN, Kent DE, Cohen DJ,. Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol 2006; 54: 68-72.
2. Schmitt J, Schäkel K, Schmitt N, Meurer M,. Systemic treatment of severe atopic eczema: a systematic review. Acta Derm Venereol 2007; 87: 100-111.
3. Krathen RA, Hsu S,. Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol 2005; 53: 338-340.
4. Vigo PG, Girgis KR, Pfuetze BL, Critchlow ME, Fisher J, Hussain I,. Efficacy of anti-IgE therapy in patients with atopic dermatitis. J Am Acad Dermatol 2006; 55: 168-170.
5. Andres C, Belloni B, Mempel M, Ring J,. Omalizumab for patients with severe and therapy-refractory atopic eczema? Curr Allergy Asthma Rep 2008; 8: 179-180.
6. Beck LA, Saini S,. Wanted: a study with omalizumab to determine the role of IgE-mediated pathways in atopic dermatitis. J Am Acad Dermatol 2006; 55: 540-541.
7. Heil PM, Maurer D, Klein B, Hultsch T, Sting G,. Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course-a randomized, placebo-controlled and double blind pilot study. J Dtsch Dermatol Ges 2010; 8: 990-998.
8. Jolles S, Hughes J, Rustin M,. The treatment of atopic dermatitis with adjunctive high-dose intravenous immunoglobulin: a report of three patients and review of the literature. Br J Dermatol 2000; 142: 551-554.
9. Jolles S, Sewell C, Webster D, et al. Adjunctive high-dose intravenous immunoglobulin treatment for resistant atopic dermatitis: efficacy and effects on intracellular cytoquine levels and CD4 counts. Acta Derm Venereol 2003; 83: 433-437.
10. Paul C, Dubertret L,. A randomized controlled evaluator blinded trial of intravenous immunoglobulin in adults with severe atopic dermatitis. Br J Dermatol 2002; 147: 518-522.